Skip to main content
Genome Announcements logoLink to Genome Announcements
. 2017 Jun 1;5(22):e00441-17. doi: 10.1128/genomeA.00441-17

Complete Genome Sequence of Escherichia coli BLR(DE3), a recA-Deficient Derivative of E. coli BL21(DE3)

Philippe Goffin a,b,, Philippe Dehottay a
PMCID: PMC5454202  PMID: 28572319

ABSTRACT

Escherichia coli BLR(DE3) is a commercially available recA-deficient derivative of BL21(DE3), one of the most widely used strains for recombinant protein expression. Here, we present the full-genome sequence of BLR(DE3) and highlight additional differences with its parent strain BL21(DE3) which were previously unreported but may affect its physiology.

GENOME ANNOUNCEMENT

Escherichia coli is widely used for the production of recombinant polypeptides, including therapeutic proteins (1). The most popular system for protein overexpression in E. coli is the isopropyl-β-d-thiogalactopyranoside (IPTG)-inducible T7 RNA polymerase cascade system, in which expression of the gene of interest is controlled by a T7 RNA polymerase promoter (e.g., on a pET vector) in a strain carrying the T7 RNA polymerase gene under control of an IPTG-inducible promoter (e.g., λDE3 lysogenic strains) (2). The genome sequence of the widely used E. coli B strain BL21(DE3) (2) is available (3). BLR(DE3) is a recA-deficient derivative of BL21(DE3) that helps stabilize plasmids containing repetitive sequences (4). According to Novagen, BLR(DE3) has the same genotype, except for a mutation in recA [Δ(srl-recA)306::Tn10], which was initially obtained in an E. coli K-12 background (5) and later transferred to BL21 (4, 6).

We sequenced the BLR(DE3) strain obtained from Novagen in order to verify whether additional differences are present in BLR(DE3) compared to BL21(DE3). We performed de novo hybrid assembly from PacBio sequencing (102,708 reads, with a mean length of 5,173 bp) and Illumina HiSeq 2000 sequencing (approx. 4,500,000 high-quality paired-end 100-bp reads) for closing gaps and correcting PacBio sequencing errors. A total of 4,306 coding sequences (CDSs), 230 pseudogenes, 85 tRNA genes, 22 rRNA genes (8 operons), and 64 noncoding RNA genes were annotated.

A comparison with BL21(DE3) indicates larger differences than expected, with two main divergent regions. First, the DE3 prophage contains three large deletions of 4.9 kb (cro-Rz), 1.8 kb (A-B), and 11.1 kb (Fi-J), suggesting the prophage is nonfunctional. As expected, the second divergent region is the recA locus. A 6.9-kb region from recA to srlR is replaced with Tn10 in BLR(DE3). Besides recA and the srl operon, BLR(DE3) thus also lacks pncC (encoding nicotinamide mononucleotide deamidase, a key enzyme of the pyridine nucleotide cycle [7]) and mtlB (encoding a lytic murein transglycosylase). Downstream of Tn10, a large region (approx. 75 kb; srlR-queE) diverges significantly from BL21(DE3), with 577 nucleotide substitutions (1 to 3 bp), short insertions/deletions (1 bp), and the replacement of an IS186 element with a full clustered regularly interspaced short palindromic repeat (CRISPR) locus, as found in E. coli MG1655. We infer that the entire ~85-kb region from recA to queE was transferred from the original K-12 background bearing the Δ(srl-recA)306::Tn10 mutation. This region contains several genes involved in metabolism and other key processes, such as DNA mismatch repair (mutS) or stress response (rpoS). Importantly, rpoS carries a nonsense mutation at codon 33, which has been shown to reduce σS activity (8). Outside the DE3 and recA loci, BLR(DE3) and BL21(DE3) contain fewer than 20 differences. Of note, these include a previously identified mutation in ilvA, a gene responsible for isoleucine auxotrophy (9).

Globally, the genome sequence of BLR(DE3) indicates that it cannot be merely considered a recA-deficient BL21(DE3) strain. The newly identified differences might contribute to a differential physiology of BLR(DE3), besides its reported impaired homologous recombination.

Accession number(s).

The complete genome sequence of Escherichia coli BLR(DE3) has been deposited at GenBank under accession number CP020368.

ACKNOWLEDGMENTS

This work was sponsored by GlaxoSmithKline Biologicals S.A., which provided the funding source, was involved in all stages of the study conduct and analysis, and took charge of the costs incurred in publishing.

We all are, or were at the time of study, employees of the GSK group of companies. P.D. reports ownership of shares in the GSK group of companies. P.G. and P.D. are named inventors on patents or patent applications related to the field of vaccine development and owned by GSK.

Footnotes

Citation Goffin P, Dehottay P. 2017. Complete genome sequence of Escherichia coli BLR(DE3), a recA-deficient derivative of E. coli BL21(DE3). Genome Announc 5:e00441-17. https://doi.org/10.1128/genomeA.00441-17.

REFERENCES

  • 1.Sanchez-Garcia L, Martín L, Mangues R, Ferrer-Miralles N, Vázquez E, Villaverde A. 2016. Recombinant pharmaceuticals from microbial cells: a 2015 update. Microb Cell Fact 15:33. doi: 10.1186/s12934-016-0437-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Studier FW, Moffatt BA. 1986. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol 189:113–130. doi: 10.1016/0022-2836(86)90385-2. [DOI] [PubMed] [Google Scholar]
  • 3.Jeong H, Barbe V, Lee CH, Vallenet D, Yu DS, Choi SH, Couloux A, Lee SW, Yoon SH, Cattolico L, Hur CG, Park HS, Ségurens B, Kim SC, Oh TK, Lenski RE, Studier FW, Daegelen P, Kim JF. 2009. Genome sequences of Escherichia coli B strains REL606 and BL21(DE3). J Mol Biol 394:644–652. doi: 10.1016/j.jmb.2009.09.052. [DOI] [PubMed] [Google Scholar]
  • 4.Novagen 2004. Competent cells user protocol. Novagen, Darmstatd, Germany. [Google Scholar]
  • 5.Csonka LN, Clark AJ. 1979. Deletions generated by the transposon Tn10 in the srl recA region of the Escherichia coli K-12 chromosome. Genetics 93:321–343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Roca A. 1997. Initial characterization of mutants in a universally conserved RecA structural motif. PhD thesis University of Wisconsin, Madison, Madison, WI. [Google Scholar]
  • 7.Galeazzi L, Bocci P, Amici A, Brunetti L, Ruggieri S, Romine M, Reed S, Osterman AL, Rodionov DA, Sorci L, Raffaelli N. 2011. Identification of nicotinamide mononucleotide deamidase of the bacterial pyridine nucleotide cycle reveals a novel broadly conserved amidohydrolase family. J Biol Chem 286:40365–40375. doi: 10.1074/jbc.M111.275818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Subbarayan PR, Sarkar M. 2004. Escherichia coli rpoS gene has an internal secondary translation initiation region. Biochem Biophys Res Commun 313:294–299. doi: 10.1016/j.bbrc.2003.11.132. [DOI] [PubMed] [Google Scholar]
  • 9.Schmidt M, Römer L, Strehle M, Scheibel T. 2007. Conquering isoleucine auxotrophy of Escherichia coli BLR(DE3) to recombinantly produce spider silk proteins in minimal media. Biotechnol Lett 29:1741–1744. doi: 10.1007/s10529-007-9461-z. [DOI] [PubMed] [Google Scholar]

Articles from Genome Announcements are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES